De Scheerder Marie-Angélique, van Bilsen Ward P H, Dullaers Melissa, Martinez-Picado Javier, Davidovich Udi, Vandekerckhove Linos
Department of General Internal Medicine, University Hospital Ghent, Ghent, Belgium.
Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
J Virus Erad. 2021 Jan 23;7(1):100029. doi: 10.1016/j.jve.2021.100029. eCollection 2021 Mar.
We aimed to investigate the motives, barriers and experiences of HIV-STAR study participants. The HIV-STAR study was an analytical HIV treatment interruption trial (ATI) aiming to evaluate the origin of viral rebound, conducted in Ghent, Belgium.
A mixed-method study was performed among 11 participants of the HIV-STAR study. Two self-administered questionnaires with 32 and 23 items, respectively, assessed motives, barriers and experiences of the research participants. In-depth interviews were conducted to further explore and understand topics that had emerged from these surveys.
Motives of ATI study participants were primarily related to the improvement of their own health perspectives and to their contribution to find an HIV cure. Barriers for ATI participation mostly related to practical issues, such as difficulty in planning study visits. Ten out of 11 participants reported a very high overall satisfaction and were willing to participate in another ATI. This satisfaction was predominantly linked to clear communication and guidance. Invasive sampling during the ATI was less of a burden than anticipated by participants. However, most participants underestimated the emotional impact of HIV treatment interruption, which was associated with feelings of uncertainty and loss of control. Risk of HIV transmission because of viral rebound was also mentioned as burdensome during this phase.
Involvement in an ATI was positively evaluated by HIV-STAR participants. Contributing to HIV cure research outweighed the burden of study participation for most participants. The latter aspects were attenuated by mutual decision making and the experience of empathy from the research team. Still, issues regarding privacy and the psychosocial impact of treatment interruption, including sexuality and HIV transmissibility, should be addressed in a better way.
我们旨在调查HIV-STAR研究参与者的动机、障碍和经历。HIV-STAR研究是一项分析性HIV治疗中断试验(ATI),旨在评估病毒反弹的起源,该试验在比利时根特进行。
对HIV-STAR研究的11名参与者进行了一项混合方法研究。分别有32项和23项的两份自填式问卷评估了研究参与者的动机、障碍和经历。进行了深入访谈,以进一步探讨和理解这些调查中出现的主题。
ATI研究参与者的动机主要与改善自身健康状况以及为找到HIV治愈方法做出贡献有关。参与ATI的障碍大多与实际问题有关,例如安排研究访视困难。11名参与者中有10名报告总体满意度非常高,并愿意参加另一项ATI。这种满意度主要与清晰的沟通和指导有关。ATI期间的侵入性采样给参与者带来的负担比预期的要小。然而,大多数参与者低估了HIV治疗中断的情感影响,这与不确定性和失去控制的感觉有关。在这一阶段,因病毒反弹导致HIV传播的风险也被认为是沉重的负担。
HIV-STAR研究的参与者对参与ATI给予了积极评价。对大多数参与者来说,为HIV治愈研究做出贡献超过了参与研究的负担。相互决策以及研究团队的同理心体验减轻了后一方面的影响。尽管如此,隐私问题以及治疗中断的社会心理影响,包括性行为和HIV传染性,仍应得到更好的解决。